This video presents updated results of two phase III trials in relapsed or refractory multiple myeloma, showing the impact of daratumumab combinations across cytogenetic risk groups.
Katja Weisel, MD
Advertisement
Articles by Katja Weisel, MD
Advertisement
Latest Updated Articles
POLLUX/CASTOR: Daratumumab Improved Myeloma Outcomes Regardless of Risk GroupPublished: June 8th 2017 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC
2
Zurletrectinib Generates Responses in Advanced NTRK Fusion Solid Tumors
3
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
4
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
5
